Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 3/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161455 | 1.00 | LGALS3 (0.44) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL20161710 | 0.84 | FUCA1 (0.47) | EPHX1 | |
| SCHEMBL20161697 | 0.77 | LGALS3 (0.55) | LGALS3LGALS1LGALS9LGALS8PYGB | |
| SCHEMBL20161323 | 0.77 | NAAA (0.47) | MAPK1PYGBGAAEPHX1EPHX2 | |
| Dextrose SCHEMBL8984701 | 0.77 | MAPK1 (0.50) | MAPK1PYGBGAAEPHX1EPHX2 | |
| SCHEMBL20161560 | 0.77 | NAAA (0.47) | MAPK1PYGBGAAEPHX1EPHX2 | |
| Decane SCHEMBL5531250 | 0.77 | LGALS3 (0.75) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| Decane SCHEMBL5527363 | 0.77 | LGALS3 (0.75) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| Dodecane SCHEMBL5581486 | 0.77 | LGALS3 (0.75) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| Dodecane SCHEMBL6726957 | 0.77 | LGALS3 (0.75) | LGALS3LGALS1LGALS9LGALS8MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | L'OREAL (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | KRT18, CUTA, GLA | LGALS3 403/4885LGALS1 408/4885LGALS9 567/4885 |
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | KRT18, CUTA, GLA | LGALS3 403/4885LGALS1 408/4885LGALS9 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.